UBS upgraded Johnson & Johnson to Buy from Neutral with an $180 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson’s (NYSE:JNJ) Revised Earnings Don’t Worry Investors
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- Johnson & Johnson price target lowered to $170 from $178 at Wells Fargo
- Biden Plans to Boost Drug Production Using Cold-War Era Law
- Roku upgraded, Lucid Group downgraded: Wall Street’s top analyst calls